Cullinan Financial Statements From 2010 to 2025
| CGEM Stock | USD 7.77 0.39 4.78% |
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
Check out the analysis of Cullinan Oncology Correlation against competitors. Cullinan Oncology LLC Company Shares Outstanding Analysis
Cullinan Oncology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cullinan Oncology Shares Outstanding | 59.01 M |
Most of Cullinan Oncology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cullinan Oncology LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Cullinan Oncology LLC has 59.01 M of shares currently outstending. This is 67.31% lower than that of the Biotechnology sector and 44.77% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 89.68% higher than that of the company.
Cullinan Oncology LLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cullinan Oncology's current stock value. Our valuation model uses many indicators to compare Cullinan Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cullinan Oncology competition to find correlations between indicators driving Cullinan Oncology's intrinsic value. More Info.Cullinan Oncology LLC is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Cullinan Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Cullinan Oncology Financial Statements
Cullinan Oncology investors utilize fundamental indicators, such as revenue or net income, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Cullinan Oncology Correlation against competitors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.